Increased vascular contractility in isolated vessels from cigarette smoking rats is mediated by basal endothelin release.
The effect of chronic cigarette smoking on endothelin modulation of vascular contraction, and CYP enzyme levels was studied in 20 male Sprague-Dawley rats. The animals were divided equally into smoking and non-smoking groups. The smoking group was exposed to 6 research cigarettes per rat per day 5 days a week for 16 weeks. The control group was sham smoked. Functional contractile studies were performed in aortas and carotid arteries to determine the regulation of vascular tone by basal release of endothelin. Liver samples were analyzed for CYP1A1 and CYP1A2 gene expression by RT-PCR. Plasma samples were assessed for endothelin-1 (ET-1) level by enzyme immuno assay (EIA). Treatment of aortas and carotid arteries with bosentan, the dual endothelin receptor antagonist, caused a significant reduction in constrictor responses of smoking rats, indicating, increase greater regulation of tone by endothelin in smoker rats compared to controls. There was a greater expression of the cytochrome P450-liver enzymes (CYP1A1 and CYP1A2) in smoker rats. Body weight gain was also significantly decreased in smoker rats. We conclude that increased endothelin release in smoker rats significantly contributes to increased arterial tone and so contribute to the cardiovascular pathophysiology associated with cigarette smoking, such as increased vascular muscularization, increased contraction, decreased dilation and possibly vasospasm.
Rahman
Mohammad M
MM
Department of Anesthesiology, Pharmacology and Therapeutics, Faculty of Medicine, 2176 Health Sciences Mall, University of British Columbia, Vancouver, BC, Canada.
Elmi
Shahrzad
S
Chang
Thomas K H
TK
Bai
Ni
N
Sallam
Nada A
NA
Lemos
Virginia S
VS
Moien-Afshari
Farzad
F
Laher
Ismail
I
D000818:Animals; D001013:Aorta, Thoracic / Q000187:drug effects* / Q000378:metabolism; D000077300:Bosentan; D002318:Cardiovascular Diseases / Q000209:etiology; D002339:Carotid Arteries / Q000187:drug effects* / Q000378:metabolism; D019363:Cytochrome P-450 CYP1A1 / Q000096:biosynthesis; D019388:Cytochrome P-450 CYP1A2 / Q000096:biosynthesis; D003580:Cytochromes; D004305:Dose-Response Relationship, Drug; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1 / Q000097:blood / Q000378:metabolism*; D004790:Enzyme Induction / Q000187:drug effects; D008099:Liver / Q000187:drug effects / Q000201:enzymology; D008297:Male; D023421:Models, Animal; D009569:Nitric Oxide / Q000378:metabolism; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D012906:Smoke / Q000009:adverse effects*; D012907:Smoking / Q000009:adverse effects* / Q000097:blood / Q000378:metabolism / Q000503:physiopathology; D013449:Sulfonamides / Q000494:pharmacology; D013997:Time Factors; D014026:Nicotiana; D014661:Vasoconstriction / Q000187:drug effects*; D015430:Weight Gain / Q000187:drug effects
D003580:Cytochromes; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1; D012906:Smoke; D013449:Sulfonamides; D009569:Nitric Oxide; C017170:Cyp1a2 protein, rat; D019363:Cytochrome P-450 CYP1A1; D019388:Cytochrome P-450 CYP1A2; D000077300:Bosentan